8-K: Journey Medical Appoints Joseph Benesch as Permanent Chief Financial Officer

Journey Medical Corporation has appointed Joseph Benesch as its permanent Chief Financial Officer, effective April 26, 2024, after he served as interim CFO since January 2023.

Summary

• Journey Medical Corporation has officially appointed Joseph Benesch as its permanent Chief Financial Officer, effective April 26, 2024.
• Mr. Benesch previously served as the interim CFO since January 27, 2023, and as Corporate Controller since November 2021.
• His compensation remains unchanged with this appointment, and any future changes will be determined by the Board's Compensation Committee.
• Mr. Benesch has over 25 years of experience in corporate financial leadership, including roles at Teligent Pharma, Torrent Pharmaceuticals, Savient Pharmaceuticals, Adare Pharmaceuticals, and Edenbridge Pharmaceuticals.
• The company highlighted his experience in technical accounting, regulatory compliance, and pharmaceutical operations as valuable assets.
• Journey Medical is a commercial-stage pharmaceutical company focused on dermatology products, currently marketing seven branded and two generic products.
• The company is anticipating potential approval of DFD-29 for rosacea treatment later this year.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the appointment of a permanent CFO and the potential for future product approvals. However, it also acknowledges risks and uncertainties, which tempers the overall sentiment.

Positives

• The appointment of Joseph Benesch as permanent CFO provides stability and continuity in the company's financial leadership.
• Mr. Benesch's extensive experience in the pharmaceutical industry and financial management is a valuable asset to the company.
• The company is progressing towards potential approval of DFD-29, which could be a significant milestone.
• The company has a portfolio of seven branded and two generic dermatology products.

Negatives

• The document highlights the company's reliance on the success of its dermatology products, which could be impacted by competition or regulatory changes.
• The company faces risks related to the development and regulatory approval of new products, including DFD-29.
• The company acknowledges the substantial doubt about its ability to continue as a going concern.

Risks

• The company's products are subject to time and cost-intensive regulation and clinical testing, which may hinder development and commercialization.
• A substantial portion of sales derive from products that may face generic competition, impacting operating income.
• The company operates in a heavily regulated industry, and future legislation could affect operations.
• Competition could limit the commercial opportunity and profitability of the company's products.
• The company relies on third parties for several aspects of its operations.
• The company's success depends on the development and regulatory approval of DFD-29 and other future product candidates.
• Clinical trials may fail to demonstrate the safety and efficacy of product candidates.
• The company faces risks related to intellectual property protection and cybersecurity.
• The company may need to raise additional capital.
• Fortress Biotech controls a voting majority of the company's common stock, which could be detrimental to other shareholders.

Future Outlook

The company is focused on upcoming milestones, including the potential approval of DFD-29 for the treatment of rosacea later this year. The company aims to drive sustainable value creation for shareholders while helping patients with their dermatology products.

Management Comments

• Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, 'Joe has been an instrumental leader to our finance and accounting team for the past few years and it will be a seamless transition as he steps into the permanent CFO role.'
• Mr. Maraoui also stated that Mr. Benesch's in-depth financial and accounting knowledge and pharmaceutical experience are valuable assets to the company.
• Mr. Benesch stated, 'I am privileged and honored to continue to lead our finance organization as we seek to drive sustainable value creation for the Company and our shareholders while helping the many patients treated with our dermatology products.'

Industry Context

This announcement is consistent with typical corporate governance practices, where interim positions are often converted to permanent roles after a period of evaluation. The appointment of a seasoned financial executive like Mr. Benesch is crucial for a company in the pharmaceutical sector, especially one focused on product development and regulatory approvals.

Comparison to Industry Standards

• The appointment of a permanent CFO is a standard practice for publicly traded companies, particularly those in the pharmaceutical industry.
• Many pharmaceutical companies, such as Teligent Pharma and Torrent Pharmaceuticals, have similar financial leadership structures, with experienced professionals overseeing financial operations.
• The transition from interim to permanent CFO is a common step, indicating the company's confidence in Mr. Benesch's abilities.
• The focus on upcoming milestones, including potential drug approvals, is typical for companies in the development stage of the pharmaceutical industry.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a permanent CFO as a positive step towards stability and growth.
• Employees may benefit from the continuity in financial leadership.
• Customers may see the potential approval of DFD-29 as a positive development for treatment options.
• Creditors may view the appointment as a sign of financial stability.

Next Steps

• The company will continue to focus on the potential approval of DFD-29 for rosacea treatment.
• The company will continue to develop and commercialize its dermatology products.
• The company will continue to monitor and manage its financial operations under the leadership of Mr. Benesch.

Key Dates

Keywords

Chief Financial Officer, CFO, Joseph Benesch, Journey Medical, Pharmaceutical, Dermatology, DFD-29, Financial Leadership, Regulatory Compliance, Corporate Controller